Frozen Shoulder and Glucose Following Corticosteroid Injection

Launched by CENTRAL LONDON COMMUNITY HEALTHCARE NHS TRUST · Jul 2, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how blood sugar levels change after a corticosteroid injection in people with frozen shoulder, a condition that causes pain and stiffness in the shoulder joint. The main goal is to see how these glucose levels are affected in individuals who do not have diabetes. In addition to this primary aim, the trial will also look at other outcomes such as physical and emotional well-being after the injection.

To be eligible for this study, participants should be between the ages of 45 and 65, have frozen shoulder symptoms for at least a month, and not have diabetes or pre-diabetes. Participants will wear a small device on their arm to monitor their blood sugar levels for 14 days after receiving the corticosteroid injection as part of their usual treatment. It's important to note that certain medical conditions or recent treatments may prevent someone from joining the study. Overall, the trial aims to provide valuable insights into the effects of corticosteroid injections on blood sugar in people with frozen shoulder.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Aged between 45 and 65
• • Without diabetes or pre-diabetes
• • Glenohumeral external rotation range is equally limited actively and passively by at least 50% compared to the contralateral side.
• • Other glenohumeral movements are equally limited actively and passively compared to the contralateral side in one or more additional planes of movement (such as hand behind the back/shoulder flexion/abduction/scaption).
• • The symptoms have been present for at least one month.
• • No significant abnormality on plain radiographs.
• • Ability to provide informed consent
• Exclusion Criteria:
• • Aged 44 and under and 66 and over
• • People with frozen shoulder secondary to significant shoulder trauma (e.g., dislocation, fracture or full thickness tear requiring surgery) or other causes (e.g., recent breast cancer surgery or radiotherapy)
• • People with prediabetes, type 1 and 2 diabetes
• • A neurological disease affecting the shoulder
• • Evidence of other shoulder disorders (e.g., inflammatory arthritis, rotator cuff disorders, glenohumeral joint instability) or with red flags consistent with the criteria set out by British Elbow and Shoulder Society (Rangan, 2015).
• • Primary osteoarthritis of the glenohumeral joint on plain radiograph
• • Calcific tendinitis
• • Who have received corticosteroid injection for shoulder pain in the last 12 weeks
• • On long term steroids or a recent short course of oral steroids
• • Currently being treated with coumarin anticoagulants, such as warfarin
• • Who have participated in another research study involving an investigational medicinal product in the past 12 weeks
• • Significant renal or hepatic impairment
• • Any other significant disease which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study.
• • Systemically unwell or with infection
• • Pregnant or breastfeeding